Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

Spinraza in Adult Spinal Muscular Atrophy

NCT03709784 · View on ClinicalTrials.gov ↗

Study Summary

This is a longitudinal, observational study of adult patients with genetically confirmed chromosome 5q SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.

Interventions

  • DRUG Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care
  • OTHER One time survey

Study Locations (11)

Arizona

  • Barrow Neurological Institute — Phoenix

District of Columbia

  • Georgetown University — Washington D.C.

Maryland

  • Johns Hopkins — Baltimore

Massachusetts

  • Massachusetts General Hospital-Harvard University — Boston

Michigan

  • Memorial Healthcare — Owosso

Missouri

  • Washington University School of Medicine — St Louis

New York

  • New York University School of Medicine — New York

Texas

  • Houston Methodist Neurological Institute — Houston

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2018-08-16
Est. Completion 2025-01-01

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03709784

The ClinicalTrials.gov registry entry for NCT03709784 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,036 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 2 interventions — of which Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03709784 reports 11 study locations spanning 11 distinct geographic areas — top geographies include Arizona, District of Columbia, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03709784 about?

NCT03709784 is a clinical study titled "Spinraza in Adult Spinal Muscular Atrophy". This is a longitudinal, observational study of adult patients with genetically confirmed chromosome 5q SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.

What is the current status of trial NCT03709784?

This trial is currently active not recruiting. The enrollment target is 148 participants. The study started on 2018-08-16. Estimated completion is 2025-01-01.

What conditions does trial NCT03709784 study?

This clinical trial studies the following conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type II. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03709784?

The interventions under investigation include: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care (DRUG), One time survey (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03709784?

This trial is sponsored by Washington University School of Medicine, which has 1,036 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03709784 being conducted?

This trial has 11 study locations across Arizona, District of Columbia, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial